• Réf :HematoStat.net ; 2 (4) : V54 Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio […]

    Published On: 27 April 2022
  • Réf :HematoStat.net ; 2 (4) : V53 Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, Martinez-Calle N, […]

    Published On: 27 April 2022
  • Réf :HematoStat.net ; 2 (4) : V52 Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Rigolin GM, Del Giudice I, […]

    Published On: 27 April 2022
  • Réf :HematoStat.net ; 2 (4) : V51 Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, […]

    Published On: 27 April 2022
  • Réf :HematoStat.net ; 2 (4) : V50 The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf […]

    Published On: 27 April 2022
  • Published On: 14 March 2022
  • Published On: 21 January 2022
  • Published On: 1 December 2021
  • Transplantation de CSH et Richter, épisode 1 Réf. :HematoStat.net ; 1 (11) : R29   Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman […]

    Published On: 30 November 2021
  • Published On: 30 November 2021